{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:55:07Z","timestamp":1781830507696,"version":"3.54.5"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100020963","name":"Japan Science and Technology Agency Moonshot Research and Development Program","doi-asserted-by":"publisher","award":["21zf0127003h001"],"award-info":[{"award-number":["21zf0127003h001"]}],"id":[{"id":"10.13039\/501100020963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JPJSA3F20230001"],"award-info":[{"award-number":["JPJSA3F20230001"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23H02867"],"award-info":[{"award-number":["23H02867"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K02613"],"award-info":[{"award-number":["25K02613"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K21295"],"award-info":[{"award-number":["24K21295"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ymthe.2026.02.032","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:58:11Z","timestamp":1773154691000},"page":"3077-3096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A mGluR1-targeted radiotheranostic strategy visualizes lesions and potentiates antitumor efficacy in melanoma and pancreatic cancer"],"prefix":"10.1016","volume":"34","author":[{"given":"Lin","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hanyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Fujinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiding","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Kokufuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsushi","family":"Kumata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wakana","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazui","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ohkubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekatsu","family":"Wakizaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Minegishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuki","family":"Nengaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Nagatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.02.032_bib1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2023.03.001","article-title":"Next generation radiotheranostics promoting precision medicine","volume":"34","author":"Pomykala","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2026.02.032_bib2","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.02.032_bib3","article-title":"Radiopharmaceuticals and their applications in medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.02.032_bib4","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ymthe.2022.12.011","article-title":"Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma","volume":"31","author":"Raninga","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.02.032_bib5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nrc.2016.71","article-title":"From Krebs to clinic: glutamine metabolism to cancer therapy","volume":"16","author":"Altman","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2026.02.032_bib6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/ng1148","article-title":"Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia","volume":"34","author":"Pollock","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2026.02.032_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2026.02.032_bib8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1249489","article-title":"Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator","volume":"344","author":"Wu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.02.032_bib9","article-title":"A 211At-labelled mGluR1 inhibitor induces cancer senescence to elicit long-lasting anti-tumor efficacy","volume":"4","author":"Xie","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2026.02.032_bib10","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.cellsig.2005.10.012","article-title":"Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1\/2 via PKCepsilon","volume":"18","author":"Mar\u00edn","year":"2006","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ymthe.2026.02.032_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejphar.2016.04.053","article-title":"Inhibition of metabotropic glutamate receptor 1 suppresses tumor growth and angiogenesis in experimental non-small cell lung cancer","volume":"783","author":"Xia","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ymthe.2026.02.032_bib12","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/jid.2010.126","article-title":"The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells","volume":"130","author":"Le","year":"2010","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ymthe.2026.02.032_bib13","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1158\/0008-5472.CAN-18-1500","article-title":"Concurrent targeting of glutaminolysis and metabotropic glutamate receptor 1 (GRM1) reduces glutamate bioavailability in GRM1+ melanoma","volume":"79","author":"Shah","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2026.02.032_bib14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s40001-022-00732-w","article-title":"A phase Ib dose-escalation study of troriluzole BHV-4157, an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors","volume":"27","author":"Silk","year":"2022","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.ymthe.2026.02.032_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/pcmr.12327","article-title":"Riluzole is a radio-sensitizing agent in an in vivo model of brain metastasis derived from GRM1 expressing human melanoma cells","volume":"28","author":"Wall","year":"2015","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.ymthe.2026.02.032_bib16","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/pcmr.12694","article-title":"A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma","volume":"31","author":"Mehnert","year":"2018","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.ymthe.2026.02.032_bib17","first-page":"255","article-title":"Radiotheranostics in oncology: Making precision medicine possible","volume":"73","author":"Aboagye","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ymthe.2026.02.032_bib18","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1038\/s41591-024-03383-y","article-title":"Eleven clinical trials that will shape medicine in 2025","volume":"30","author":"Webster","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.02.032_bib19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/mt.2010.296","article-title":"Epidermal growth factor receptor-targeted 131I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene","volume":"19","author":"Klutz","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.02.032_bib20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2967\/jnumed.108.058651","article-title":"MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy","volume":"51","author":"Sgouros","year":"2010","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ymthe.2026.02.032_bib21","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1158\/0008-5472.CAN-19-2806","article-title":"\u03b1-Particle-emitter radiopharmaceutical therapy: resistance is futile","volume":"79","author":"Sgouros","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2026.02.032_bib22","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2967\/jnumed.116.187021","article-title":"\u03b1-Versus \u03b2-emitting radionuclides for pretargeted radioimmunotherapy of carcinoembryonic antigen-expressing human colon cancer xenografts","volume":"58","author":"Heskamp","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ymthe.2026.02.032_bib23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2967\/jnumed.119.230946","article-title":"131I-IITM and 211At-AITM: two novel small-molecule radiopharmaceuticals targeting oncoprotein metabotropic glutamate receptor 1","volume":"61","author":"Xie","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ymthe.2026.02.032_bib24","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1002\/ijc.28842","article-title":"Molecular imaging of ectopic metabotropic glutamate 1 receptor in melanoma with a positron emission tomography radioprobe 18F-FITM","volume":"135","author":"Xie","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2026.02.032_bib25","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s00259-011-1995-6","article-title":"Imaging for metabotropic glutamate receptor subtype 1 in rat and monkey brains using PET with 18F-FITM","volume":"39","author":"Yamasaki","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ymthe.2026.02.032_bib26","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2967\/jnumed.115.162461","article-title":"The PET radioligand 18F-FIMX images and quantifies metabotropic glutamate receptor 1 in proportion to the regional density of its gene transcript in human brain","volume":"57","author":"Zanotti-Fregonara","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ymthe.2026.02.032_bib27","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.2967\/jnumed.112.105908","article-title":"In vivo measurement of the affinity and density of metabotropic glutamate receptor subtype 1 in rat brain using 18F-FITM in small-animal PET","volume":"53","author":"Yamasaki","year":"2012","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ymthe.2026.02.032_bib28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ctrv.2010.08.004","article-title":"Systematic review and meta-analysis of radiotherapy in various head and neck cancers: comparing photons, carbon-ions and protons","volume":"37","author":"Ramaekers","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ymthe.2026.02.032_bib29","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S2468-1253(19)30347-4","article-title":"The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"4","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2026.02.032_bib30","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/35039564","article-title":"Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor","volume":"407","author":"Kunishima","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.02.032_bib31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1126\/science.abb5916","article-title":"Senolysis by glutaminolysis inhibition ameliorates various age-associated disorders","volume":"371","author":"Johmura","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2026.02.032_bib32","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.cell.2005.02.003","article-title":"Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors","volume":"120","author":"Campisi","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.02.032_bib33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10555-020-09875-w","article-title":"Caveolin-1, a master regulator of cellular senescence","volume":"39","author":"Volonte","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ymthe.2026.02.032_bib34","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.ymthe.2024.04.030","article-title":"Sirt6 protects retinal ganglion cells and optic nerve from degeneration during aging and glaucoma","volume":"32","author":"Xia","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.02.032_bib35","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cell.2008.03.039","article-title":"Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network","volume":"133","author":"Kuilman","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.02.032_bib36","first-page":"538","article-title":"MIRDOSE: personal computer software for internal dose assessment in nuclear medicine","volume":"37","author":"Stabin","year":"1996","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ymthe.2026.02.032_bib37","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2307\/3579579","article-title":"Alpha-Emitters for Medical Therapy: Workshop of the United States Department of Energy: Denver, Colorado, May 30-31, 1996","volume":"148","author":"Feinendegen","year":"1997","journal-title":"Radiat. Res."},{"key":"10.1016\/j.ymthe.2026.02.032_bib38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.neuropharm.2016.02.011","article-title":"Metabotropic glutamate receptors in cancer","volume":"115","author":"Yu","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ymthe.2026.02.032_bib39","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0024-3205(01)01454-0","article-title":"Characterization of mouse melanoma cell lines by their mortal malignancy using an experimental metastatic model","volume":"70","author":"Nakamura","year":"2002","journal-title":"Life Sci."},{"key":"10.1016\/j.ymthe.2026.02.032_bib40","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1158\/0008-5472.CAN-19-0859","article-title":"Cellular and genetic determinants of the sensitivity of cancer to \u03b1-particle irradiation","volume":"79","author":"Yard","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2026.02.032_bib41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijrobp.2019.02.047","article-title":"Biological principles of stereotactic body radiation therapy (SBRT) and stereotactic radiation surgery (SRS): indirect cell death","volume":"110","author":"Song","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ymthe.2026.02.032_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae172","article-title":"Potential for in vivo visualization of intracellular pH gradient in the brain using PET imaging","volume":"6","author":"Yamasaki","year":"2024","journal-title":"Brain Commun."},{"key":"10.1016\/j.ymthe.2026.02.032_bib43","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.apradiso.2014.09.012","article-title":"Production of 211At by a vertical beam irradiation method","volume":"94","author":"Nagatsu","year":"2014","journal-title":"Appl. Radiat. Isot."},{"key":"10.1016\/j.ymthe.2026.02.032_bib44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.nucmedbio.2016.11.009","article-title":"Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for 211At labeling at high activities and radiation doses of 211At \u03b1-particles","volume":"46","author":"Pozzi","year":"2017","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ymthe.2026.02.032_bib45","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1021\/jm501845n","article-title":"Synthesis and evaluation of 4-halogeno-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-[11C]methylbenzamide for imaging of metabotropic glutamate 1 receptor in melanoma","volume":"58","author":"Fujinaga","year":"2015","journal-title":"J. Med. Chem."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626001188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626001188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:36:26Z","timestamp":1781829386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626001188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1525001626001188"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.02.032","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A mGluR1-targeted radiotheranostic strategy visualizes lesions and potentiates antitumor efficacy in melanoma and pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.02.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}